Skip to main content

Bio-Rad Laboratories, Inc.

corporate_fare Company Profile

Bio-Rad Laboratories, Inc.

BIO·NYSE·Industrial Applications And Services·CIK 0000012208

Bio-Rad Laboratories, Inc. is a multinational life science and clinical diagnostics company that develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables. The company has direct operations in over 36 countries outside the United States, with sales efforts supplemented by distributors and agents in certain locations. Bio-Rad operates in two industry segments: Life Science and Clinical Diagnostics, both operating worldwide. For the year ended December 31, 2025, the Life Science segment generated approximately 40% of consolidated net sales, and the Clinical Diagnostics segment generated approximately 60%. Approximately 40% of consolidated net sales for the year ended December 31, 2025, came from the U.S., and approximately 60% from international locations, with Europe being the largest international region. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials such as cells, proteins, and nucleic acids. These products are utilized in research and biopharmaceutical laboratory environments, biopharmaceutical manufacturing, quality control processes, food safety testing, and science education applications. This segment serves the research market, supporting scientific discovery from early research through clinical and applied use, offering thousands of life science products globally. The estimated worldwide sales of products in the markets served by this segment are approximately $19 billion. Principal customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, and food producers and testing laboratories. The Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics solutions, test kits, and specialized quality controls for clinical laboratories in the global diagnostics market.

Bio-Rad Laboratories, Inc. (NYSE:BIO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 13 items for BIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for BIO spans 10-Q, 8-K, DEF 14A, 10-K.

Recent high-impact activity:

  • Bio-Rad Q3 Revenue Edges Past Estimates as Clinical Diagnostics Offsets Life Science Weakness
  • Bio-Rad 10-Q Details Q3: $458.6M GAAP Profit Is a Sartorius Mark; Operations Lost $49.7M
  • Bio-Rad Q3 2026: Non-GAAP EPS $2.65, GAAP Profit $458.6M on Sartorius Mark, Outlook Held
  • Bio-Rad to Slash Jobs, Shut Facilities in $80–90M Restructuring Push
  • Bio-Rad Q2 Revenue Beats by $27M on Diagnostics Strength, Reaffirms Outlook

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.58B
Net Income
$759.9M
Diluted EPS
$27.85
Op. Cash Flow
$532.2M
Free Cash Flow
$374.6M
Gross Profit
$1.34B
Operating Income
$47.2M
Cash & Equivalents
$529.8M
Total Debt
$1.2B
Debt / Equity
0.16×
Net Margin
29.4%
Shares Outstanding
27.26M sh
Source: 10-K · filed 2026-02-13 · accession 0000012208-26-000010

Short Interest & Short Volume

5.07 days to cover

FINRA reported short interest of 1,156,915 shares in BIO as of the October 30, 2026 settlement, a 5.4% increase from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 84.7% of BIO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,156,915 shares as of October 30, 2026
Change vs prior period▲ 5.4%
Days to cover5.07 at avg daily volume of 228,195
Daily short volume (FINRA facilities)84.7% of 67,294 shares on November 20, 2026
5-day average short volume84.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$358.9
52-week range · as of 2026-11-04 $236.73 – $396.23
Market cap
$9.71B
Volume
182.3K (0.7× avg)
3-mo avg 254.4K
Live data · 2026-11-21 13:08 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BIO - Latest Insights

BIO
Nov 04, 2026, 5:15 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $379.29
Real-time Price: $358.90 info
Change: -$20.39 (-5%) info
Market Cap: $9.709B info
BIO
Nov 04, 2026, 4:19 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $379.29
Real-time Price: $358.90 info
Change: -$20.39 (-5%) info
Market Cap: $9.709B info
BIO
Nov 04, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $379.29
Real-time Price: $358.90 info
Change: -$20.39 (-5%) info
Market Cap: $9.709B info
BIO
Aug 04, 2026, 5:42 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $326.33
Real-time Price: $358.90 info
Change: +$32.57 (+10%) info
Market Cap: $9.709B info
BIO
Aug 04, 2026, 4:27 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $326.33
Real-time Price: $358.90 info
Change: +$32.57 (+10%) info
Market Cap: $9.709B info
BIO
Aug 04, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $326.33
Real-time Price: $358.90 info
Change: +$32.57 (+10%) info
Market Cap: $9.709B info
BIO
May 17, 2026, 8:03 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $247.53
Real-time Price: $358.90 info
Change: +$111.37 (+45%) info
Market Cap: $9.709B info
BIO
Apr 30, 2026, 4:31 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $280.12
Real-time Price: $358.90 info
Change: +$78.78 (+28%) info
Market Cap: $9.709B info
BIO
Apr 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $287.84
Real-time Price: $358.90 info
Change: +$71.06 (+25%) info
Market Cap: $9.709B info
BIO
Mar 25, 2026, 4:17 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $273.60
Real-time Price: $358.90 info
Change: +$85.30 (+31%) info
Market Cap: $9.709B info
BIO
Feb 19, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $271.90
Real-time Price: $358.90 info
Change: +$87.00 (+32%) info
Market Cap: $9.709B info
BIO
Feb 12, 2026, 9:50 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $255.00
Real-time Price: $358.90 info
Change: +$103.90 (+41%) info
Market Cap: $9.709B info
BIO
Feb 12, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $292.42
Real-time Price: $358.90 info
Change: +$66.48 (+23%) info
Market Cap: $9.709B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets